Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 5,631.00
+23.00 (0.41%)
Mar 5, 2026, 3:30 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.19T JPY in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to 4.52T, down -5.56% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.52T
Revenue Growth
-5.56%
P/S Ratio
1.98
Revenue / Employee
94.08M
Employees
47,455
Market Cap
8.86T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.68B | 8.65% |
| Mar 31, 2013 | 1.56T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Toho Holdings | 1.54T |
| Eisai | 808.19B |
| Shionogi & | 465.38B |
| Sumitomo Pharma | 453.40B |
| Towa Pharmaceutical | 269.92B |
| Sawai Group Holdings | 200.68B |
| Tsumura & Co. | 189.50B |
| Nippon Shinyaku | 166.05B |
Takeda Pharmaceutical Company News
- 12 hours ago - Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 3 days ago - Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - Business Wire
- 13 days ago - Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis - Business Wire
- 22 days ago - Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Benzinga
- 23 days ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire
- 23 days ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 23 days ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 23 days ago - Takeda deepens AI drug discovery push with $1.7 billion Iambic deal - Reuters